SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Reports indicate that SGLT-2 inhibitors notably boost autophagy in liver macrophages through the AMPK/mTOR signaling axis, alleviating liver damage in T2DM mice with NAFLD [39].